NEXMED

The Minimum Effective GLP-1 Dose: Do You Need the Maximum Dose?

Not everyone needs the maximum GLP-1 dose. What trials show about lower doses and what the official prescribing information allows.

Nexmed Editorial · Updated 30 September 2026
The Minimum Effective GLP-1 Dose: Do You Need the Maximum Dose?

More and more patients on Wegovy, Mounjaro, or Ozempic are asking the same question: if I'm losing weight well on a lower dose, do I still need to go up to the maximum dose? The short answer: not everyone needs the maximum dose, and the official prescribing information leaves room for that. But "less" doesn't mean "just as much," and the decision is made with your doctor, not on your own.

In short: in large trials, lower doses produced less weight loss than the maximum dose, but still substantial weight loss. With tirzepatide (Mounjaro), 5 mg led to −15.0% at 72 weeks, compared with −20.9% on 15 mg. The prescribing information allows staying on a lower dose if the higher one isn't tolerated. The "minimum effective dose" is an individual decision, made with your doctor.

What the "minimum effective dose" is

The minimum effective dose is the lowest dose at which treatment achieves its goal for you — weight loss, blood sugar control, or maintenance — with side effects you can tolerate. It isn't a fixed number. It depends on:

  • the goal of treatment: active weight loss or maintaining weight already lost;
  • your individual response: some people respond very well to low doses, others don't;
  • side effects: nausea, vomiting, or constipation usually increase with the dose (see Wegovy and Mounjaro side effects);
  • other conditions: diabetes, heart disease, or liver disease can change the goal. For some patients, the benefits for the heart and kidneys matter as much as weight.

The maximum doses in trials were chosen to show the largest possible effect on average. They are not a target every patient has to reach.

What the trials show: lower dose, smaller result, but still meaningful

Tirzepatide (Mounjaro): the SURMOUNT-1 trial

The SURMOUNT-1 trial (New England Journal of Medicine, 2022) enrolled 2,539 adults with obesity and without diabetes, treated for 72 weeks.

DoseMean weight lossLost at least 5%Stopped treatment due to side effects
5 mg−15.0%85%4.3%
10 mg−19.5%89%7.1%
15 mg−20.9%91%6.2%
Placebo−3.1%35%2.6%

What stands out: 5 mg delivered, on average, about three-quarters of the effect of the 15 mg dose, and the proportion of people who lost at least 5% was nearly the same. The difference between 10 mg and 15 mg was small. For a comparison with semaglutide, see Mounjaro vs Wegovy. More details in our article on Mounjaro 5, 10, and 15 mg.

Semaglutide: the STEP 2 trial

The STEP 2 trial (The Lancet, 2021) compared two doses of semaglutide in 1,210 adults with type 2 diabetes and excess weight over 68 weeks:

  • 2.4 mg (the Wegovy dose): −9.6% on average;
  • 1.0 mg (a dose used in diabetes, as with Ozempic): −7.0% on average;
  • placebo: −3.4%.

Gastrointestinal side effects occurred in 63.5% of patients on 2.4 mg, 57.5% of those on 1.0 mg, and 34.3% on placebo.

Weight maintenance: the SURMOUNT-MAINTAIN trial

The newest trial on this topic (The Lancet, 2026) tested exactly the question "can I lower my dose after I've lost weight?". After 60 weeks of treatment at the maximum tolerated dose of tirzepatide, patients were split into three groups: they continued the maximum dose, stepped down to 5 mg, or switched to placebo. At the end (week 112):

  • maximum dose: −21.9% from starting weight;
  • 5 mg: −16.6%;
  • placebo: −9.9%.

The authors conclude that stepping down to 5 mg may be a valuable alternative to stopping treatment, but that the response varies from person to person. We explain the trial in detail in a dedicated article.

What the official prescribing information says

The prescribing information doesn't require anyone to stay on the maximum dose at all costs:

  • Wegovy (European SmPC): the dose is increased gradually, every 4 weeks, from 0.25 mg to 2.4 mg. If significant gastrointestinal effects occur, the SmPC recommends delaying the dose increase or going back to the previous dose. For obesity, a 7.2 mg dose is now also available in the EU, so the dose range has widened in both directions.
  • Wegovy (US prescribing information, FDA): if 2.4 mg isn't tolerated, the maintenance dose can be reduced to 1.7 mg.
  • Mounjaro (European SmPC): treatment starts at 2.5 mg, and the recommended maintenance doses are 5, 10, and 15 mg. In other words, 5 mg is an official maintenance dose, not just an intermediate step.
  • Ozempic (for type 2 diabetes): the usual maintenance doses are 0.5 mg or 1 mg.

The 2.5 mg dose of Mounjaro and the 0.25 mg dose of Ozempic/Wegovy are starting doses, not maintenance doses.

When a lower dose may make sense

Situations worth discussing with your doctor:

  • side effects that don't go away on the higher dose;
  • you've reached your target weight and are entering the maintenance phase;
  • your weight loss is already good on your current dose;
  • the cost of treatment.

What not to do: lower your dose yourself "by estimate," split a pen into your own doses, or buy "microdosed" products online. Pens are designed for fixed doses, and hand-measured doses have led to real overdoses. We explain why in our article on dosing errors.

If you and your doctor are testing a lower dose, a GLP-1 dose tracker such as Reko (partner app, iPhone) shows your doses, weight and side effects over time, so the effect of each change is easy to see.

Conclusion

The maximum dose isn't mandatory for everyone. Trials show that lower doses have a real effect, even if smaller on average, and that for some patients the difference isn't worth the extra side effects. Choosing the right dose, however, is a medical decision that takes into account your goals, other conditions, and how you respond to treatment. As a starting point, here is how to talk to your doctor about a lower dose.

Frequently asked questions

Can I lose as much weight on a lower dose? On average, no. In SURMOUNT-1, 5 mg of tirzepatide led to −15.0%, compared with −20.9% on 15 mg. Individually, though, some patients respond very well to low doses. Only tracking your progress over time, together with your doctor, will show that.

Is 5 mg of Mounjaro an "official" maintenance dose? Yes. The European Mounjaro SmPC lists 5, 10, and 15 mg as recommended maintenance doses.

Can I stay on 1.7 mg of Wegovy? The US prescribing information explicitly allows 1.7 mg as a maintenance dose if 2.4 mg isn't tolerated. The European SmPC recommends returning to the previous dose if significant gastrointestinal effects occur. Your doctor makes the decision.

If I lower my dose, will I regain the weight? Not necessarily, but the risk is higher than if you stay on the full dose. In SURMOUNT-MAINTAIN, 25% of patients switched to 5 mg regained at least half of the weight they had lost, compared with 8% on the maximum dose and 67% on placebo.

Can I lower my dose myself? No. Any dose change should be made only with the agreement of the doctor who prescribed your treatment.

Useful calculators

The "GLP-1 Dose" series

  1. The minimum effective GLP-1 dose: do you need the maximum dose?
  2. Mounjaro 5 mg vs 10 mg vs 15 mg: what the trials show
  3. Lowering the dose after weight loss: the SURMOUNT-MAINTAIN trial
  4. GLP-1 microdosing: what's real and what's marketing
  5. Ozempic overdose: why you shouldn't calculate your own dose
  6. Reducing your GLP-1 dose: how to talk to your doctor

Sources

  • Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216. doi:10.1056/NEJMoa2206038
  • Davies M et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397:971-984. doi:10.1016/S0140-6736(21)00213-0
  • Tirzepatide for maintenance of bodyweight reduction in people with obesity (SURMOUNT-MAINTAIN). Lancet. 2026;407:2305-2318. doi:10.1016/S0140-6736(26)00656-2
  • Summary of Product Characteristics (SmPC): Wegovy, Mounjaro (European Medicines Agency); Wegovy prescribing information (FDA).

Educational material, updated September 2026. It does not replace a medical consultation. Do not change the dose, frequency, or method of administration of a medication without the agreement of the doctor who prescribed it.

This article is for general information only and does not replace advice from your doctor or pharmacist. Do not start, stop or change a treatment without medical supervision.

More on weight loss & GLP-1